JNJ vs PFE: fair value comparison
Johnson & Johnson and Pfizer Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. JNJ carries the stronger quality grade.
| JNJ | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $265.58 | $27.72 |
| 12-month range | $185.08–$271.19 | $24.23–$28.55 |
| Sector rank | #108 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | C | D |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Fairly Valued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: JNJ fair value analysis · PFE fair value analysis